MUTANT LUCIFERASES

Abstract: Proteins are provided having luciferase activity with lower Km than wild-type luciferases by altering the amino acid residue at position 270 of the wild-type to an amino acid other than glutamate. Greater heat stability than wild-type luciferases while retaining the lower Km is provided by also replacing the glutamate equivalent to that at position 354 of Photinus pyralis luciferase or 356 of Luciola luciferases with an alternative amino acid, particularly lysine and/or the amino acid residue at 215 of Photinus pyralis and 217 of the Luciola species with a hydrophobic amino acid. DNA, vectors and cells that encode for and express the proteins are also provided as are test kits and reagents for carrying out luminescence assays using the proteins of the invention.

Description: MUTANT LUCIFERASES The present invention relates to novel proteins having luciferase activity and to DNA and vectors encoding for their expression. Particularly the present invention provides luciferases having lower K m for the substrate ATP than existing native and recombinant luciferases of wild and altered wild type. Firefly luciferase catalyses the oxidation of luciferin in the presence of ATP, Mg 2+ and molecular oxygen with the resultant production of light. This reaction has a quantum yield of about 0.88 (see DeLuca & McElroy (1978) and Seliger & McElroy (I960)) and this light emitting property has led to its use in luminometric assays where ATP levels are being measured. Luciferase is obtainable directly from bodies of fireflies or by expression from microorganisms including recombinant DNA constructs encoding for the enzyme. Significant species from which the enzyme may be obtained, or DNA encoding for it derived, are the Japanese GENJI and HEIKE fireflies Luciola cruciata and Luciola lateralis. the East European Firefly Luciola mingrelica. the North American firefly (Photinus pyralis) and the glow-worm and the European glow-worm Lampyris noctiluca. The heat stability of wild and recombinant type luciferases is such that they lose activity quite rapidly when exposed to temperatures in excess of about 30°C, particularly over 35°C, and this renders the enzyme deficient when used at high ambient temperatures. It is known that Japanese firefly luciferase can be heat stabilised by mutating it at its position 217 to replace a threonine residue by an isoleucine residue (Kajiyama and Nakano (1993) Biochemistry 22 page 13795 to 13799); pH stability and specific activity also being increased. Copending patent application GB 9405750.2 discloses an amino acid substitution that is capable of increasing the thermostability of inter alia. Photinus pyralis which can be used with the change at 217 to provide luciferase that is relatively heat stable at 50°C or more. The present invention relates to a further enhancement of the properties of luciferase enzyme making them suitable for use in assays based upon the detection of adenosine triphosphate relatively low levels. This enhancement is provided by changing the amino acid at the positio corresponding to position 270 in the Photinus pyralis luciferase amino acid sequence whereby th Michaelis-Menten constant (K m ) of the enzyme is decreased as compared to a correspondin luciferase having wild-type sequence. This corresponds to amino acid 272 in Luciola mingrelic Luciola cruciata and Luciola lateralis. It also corresponds to amino acid 270 in Lampris Noctiluca. The present enhancement further provides luciferases that are characterised by the ability oxidis D-luciferin with light emission of a different wavelength to that of wild-type luciferase. thu allowing them to be used as specific labels in binding assays wherein the wavelength of lig emitted is characteristic of a particular labelled material being present, or allows DNA encoding fo the luciferases to be used as a reporter DNA for genetically engineered cells and cells derive therefrom. Thus in the first aspect of the present invention there is provided a protein having luciferase activit and having over 60% homology of amino acid sequence with that of Photinus pyralis. Luciol mingrelica. Luciola cruciata or Luciola lateralis characterised in that the amino acid residu corresponding to residue 270 of Photinus pyralis luciferase and residue 272 of Luciola mingrelic Luciola cruciata and Luciola lateralis luciferase is an amino acid other than glutamate. Preferabl is characterised in that it comprises a conserved amino acid sequence F(1)XE(2)FL wherein (1) i D or E, (2) is T or L and X is the amino acid other than glutamate; F, E. L. D and T each relating t the corresponding amino acid as provided for by the single letter amino acid code. The preferred amino acid X so far determined is lysine. or an analogue or modification thereo Other preferred amino acids include arginine, glutamine and alanine. In still more preferred forms of the present invention the protein of the invention also has the amin acid at the position corresponding to amino acid 217 of the Luciola firefly luciferases or 215 Photinus pyralis changed to a hydrophobic amino acid, preferably to isoleucine, leucine or valine analogue or these and/or has the amino acid at the position corresponding to amino acid 356 of th Luciola firefly luciferase or 354 of Photinus pyralis changed to an amino acid other than glutamat particularly to lysine, arginine. leucine, isoleucine or histidine or analogues or modifications these. In a second aspect of the invention there is provided DNA encoding for the protein of the invention and in a third aspect there is provided a vector, particularly a plasmid, comprising a luc gene (the gene encoding for luciferase) in such a form as to be capable of expressing the protein of the invention. Such forms are those where the vector includes DNA sequences capable of controlling the expression of the protein of the invention such that when incorporated into a microorganism host cell the protein may readily be expressed as required, if necessary by addition of suitable inducers. The luc genes for Photinus pyralis, Luciola mingrelica. Luciola cruciata and Luciola lateralis are all known and isolatable by standard molecular biology techniques. This is also the case for Lampris noctiluca. Photinus pyralis luc gene is commercially available from Promega as the plasmid pGEM-luc. Thus convenient methods and sources for deriving starting material for production of DNA of the invention are (i) use of naturally occurring firefly genomic DNA and amplifying the luc gene from it using eg, PCR, (ii) pGEM and (iii) pGLD7 plasmid of Kajiyama and Nakano. Further genes encoding for proteins having luciferase activity, ie the activity of oxidising luciferin with the emission of light, will also be suitable sources for starting material for obtaining a DNA, and ultimately through gene expression, a protein of the invention. Suitable vectors for use in manipulating wild type or other luc gene DNA in order to produce th DNA of the invention will be any vector in which the DNA can be contained within whil alteration of the naturally occurring glutamate to an alternative amino acid is carried out. Fo chemically induced mutagenesis, eg using agents such as hydroxylamine, this is not particularl critical and many suitable vectors will occur to those skilled in the art that will allow eas manipulation of the gene before and after the mutagenic process. It may be preferred to specificall mutate the luc gene at the glutamate and thus a site directed mutagenesis operation will be required Such operations may be most easily carried out in vectors and these will be well known to thos skilled in the art. For expression of luc genes of wild and known type, and those of the present invention suitabl vectors include pKK223-3, pDR540 (available from Boehringer Mannheim) and pT7-7; the firs two having the tac promoter under control of the lactose repressor allowing expression to b induced by presence of isopropyl-thiogalactoside (IPTG). pT7-7 allows control by the T7-RN polymerase promoter and thus provides the basis for a very high level of gene expression in E. coli cells containing T7 RNA polymerase. Of these vectors expression is found to be highest when th luc genes are inserted into the pT7-7 vector. Expression of luciferase from a luc gene inserted into p K223-3 and pDR540 results in th expression of wild-type N-terminal sequence luciferase whilst expression from a luc gene inserte into pT7-7 results in synthesis of a fusion protein with extra N-terminal amino acids A-R-I-Q. Th ribosome binding site and start codon of the luc gene in each of the respective vectors with the lu gene present (named constructs pPW204, pPWl l ό and pPW304) are shown in Table 1 of th Examples. pPW601a referred to below is derived by removing the unique Xho I site pPWl 16. A third aspect of the present invention provides cells capable of expressing the proteins of the invention; methods for producing such proteins using these cells and test kits and reagents comprising the proteins of the invention. Also provided are assay methods wherein ATP is measured using luciferin/luciferase reagents, as is well known in the art, characterised in that the luciferase is a protein of the invention. Luciferase preparations of the invention are relatively low in K m with respect to the corresponding wild type and recombinant luciferases, and preferred double and triple change luciferases (ie 215; 270; 354 changed Photinus or 217; 272; 356 changed Luciola. or 215; 270; 354 changed L. noctiluca also have the property of relative thermostability at >0-70°C, particularly 37-60°C, and especially 40-50°C. Thus the present invention has been established as not preventing the thermostability enhancements of other contemporaneous and previous work by the present inventors and others from being used. Any cell capable of expressing heterologous protein using DNA sequences in its DNA, or in vectors such as plasmids contained in the cell, may be used to express the proteins of the invention. Typical of such cells will be yeast and bacterial cells such as Saccharomyces cerevisiae and Escherichia coli cells, but many other host organisms suitable for the purpose of protein expression will occur to those skilled in the art. The protein may be expressed as a protein of similar structure to native and known recombinant luciferases. or may be expressed as a fusion or conjugate of such proteins with other amino acids, peptides, proteins or other chemical entities, eg the A-R-I-Q sequence above. It will be realised by those skilled in the art that certain hosts may have particular codon preferences, eg bacteria in some cases use different codons to yeast, and thus the DNA incorporated into such a host may advantageously be altered to provide a degenerate codon for a given amino acid that will give more favourable expression in that host. Such degenerate DNAs are of course included in the scope of the DNA of the invention. E. coli BL21 (DE3) is one suitable host and has the T7 RNA polymerase integrated stably into it chromosome under control of the inducible lacUV5 promoter and is thus compatible with pT7- derived constructs. E. coli B strains like BL21 lack the Ion protease and the ompT outer membrane protease. Thes deficiencies can help to stabilise the expression and accumulation of foreign proteins in E. coli. Assays of crude extracts of E. coli BL21 (DE3) containing each of the three expression construct described above indicated that the highest levels of expression of luciferase were obtained fro cells containing the construct pPW304 (see Table 2). Other suitable cell lines, such as that of the _ coli JM109 cells used in the Examples below will occur to those skilled in the art. The proteins, DNA, vectors and cells of the invention will now be described by way of illustratio only by reference to the following non-limiting Examples. Figures, Tables and Sequence listing. Further proteins, conjugates of proteins, DNA, vectors and cells, and assays and test kit incorporating any of the above will occur to those skilled in the art in the light of these. FIGURES Figure 1 : shows a restriction map of plasmid pPW204 derived from pKK223-3 by insertion of a luc gene as described in the Examples below. Figure 2: shows a restriction map of plasmid pPWl 16 derived from pDR540 by insertion of a luc gene as described in the Examples below. Figure 3: shows a restriction map of plasmid pPW304 derived from pT7-7 by insertion of a luc gene as described in the Examples below. Figure 4: shows a restriction map of plasmid pPW601a derived from pDR540 and BamHl/Sstl fragment from pGEM-/wc with the Xho site removed. Figure 5: shows a graph of heat inactivation of recombinant wild-type Photinus luciferases (Sigma), K m changed luciferase of the invention, the thermostable 354 lysine mutant provided by copending GB 9405750.2 and K m /354 lysine double mutant of the present invention incubated at a given temperature for 16 minutes as described in the Examples below. Figure 6: shows a restriction map of pT7-7 after Tabor. SEQUENCE LISTING: The sequence listing provided at the end of this specification describes DNA and amino aci sequences as follows: SEQ ID No 1 : shows the DNA sequence of a DNA encoding for luciferase of the inventio wherein the Photinus pyralis wild-type codon at 81 1 to 813 is mutated; for lysine only the base 81 1 is mutated to an A. It also shows the position for introducing thermostability at 1063-65. SEQ ID No 2: shows the amino acid sequence of a protein of the invention wherein the Photin pyralis wild-type amino acid 270 glutamate has been changed to a residue Xaa other tha glutamate. SEQ ID No 3: shows the sequence of the oligonucleotide used for the SDM mutation of pPW601 to give a lysine instead of glutamate at position 270. SEQ ID No 4: shows the amino acid sequence of a protein of the invention wherein the Photin pyralis wild-type amino acid 270 glutamate has been changed to lysine and the 354 amino aci changed to lysine. SEQ ID No 5: shows the sequence of the oligonucleotide used for the SDM mutation of pPWόOl to give a lysine instead of glutamate at position 354. EXAMPLES Example 1 ; Production of plasmids containing DNA of the invention Plasmids pKK223-3 and pDR540 were obtained form Boehringer Mannheim; pDR540 is also available from Pharmacia Biotech St Albans UK. Phagemid pBluescript II SK(+) was obtained from Stratagene La Jolla, USA. E____\i strain BL21 (DE3) was used for the expression of luciferase from pT7-7 derived plasmids and E. coli strain JM109 (4) was used in all cloning experiments and for the expression of luciferase from pDR540 derived plasmids. Plasmid pT7-7 (see Current protocols in Molecular Biology Vol II Section 16.2.1) was obtained from Stan Tabor, Dept of Biol Chem, Harvard Medical School, Boston, Mass 02115 and (as shown in Figure 6) contains T7 RNA polymerase promoter ølO and the translation start site for the T7 gene 10 protein (T7 bp 22857 to 22972) inserted between the PvuII and Clal sites of pT7-5. Unique restriction sites for creation of fusion proteins (after filling in 5' ends) are Frame 0: EcoRl; Frame 1 : Ndcl, Smal, Clal; Frame 2: BamHI, Sail, Hindlll. Sad site of the original polylinker is removed by deletion and an additional Xbal site is provided upstream of the start codon. As stated in the preamble to the Figures, pPW204 was derived from pKK223-3; pPWl lό was derived from pDR540; pPW304 derived from pT7-7; each by insertion of a luc gene derived from Promega pGEM-/wc using standard restriction endonuclease and ligation techniques while pPW601 was created by cloning the luc gene and BamHI /Sstl fragment from pGEM-/«c into pDR540 and pPWόOla as derived by removing the unique Xho I site in the polylinker of the plasmid. pPW601a contains a unique recognition site for Ava I which simplifies the SDM procedure for luciferase amino acid 354 changes. For production of pPW304, pT7-7 is digested with EcoRI, the ends filled using Klenow fragment, the product digested with Sail and the DNA gel purified; pGEM-/wc is digested with Bam HI, the overhangs produced digested with MBN, the product digested with Sail and the l .Kb fragment produced purified and ligated to the purified pT7-7 DNA. Transformation of plasmids into BMH 71-18 mut S cells was carried out using a Bio-Rad Gen Pulser version 2-89. For production of pPW601 clones harvested cells and purified mixed plasmi pool containing mutated and parental plasmids were provided and secondary restriction digest wit Aval was carried out before transformation into E. coli JM109 cells. These cells were plated o selective media (LB agar + 50 μg/ml ampicillin) and clones screened by purifying their plasmi DNA and analysing for the desired change. Plasmid DNA was purified using alkaline lysi (Birnboim & Doly (1979) Nucleic Acids Research 7, pl513). Relative levels of expression of luciferase from each of the constructs pPW204, pPWl lό an pPW304 are 0.1 : 0.5: 1.0 from E. coli BL21 (DE3). Cells were grown in LB at 37°C to an OD 60 of 0.3 then induced with IPTG and growth allowed to continue for 4 hours after which crude extrac was prepared and luciferase activity measured. TABLE 1 : Ribosome binding sites (underlined) and start codons in the expression constructs used in Example 1. pPW304 ΔAGGΔΩATATACAT ATG* CGT AGA ATT CAA ATG pPWl lό Ai j-ΔAACΔGiiΔTCCA ATG* pPW204 ΔGXzΔAACAGCAA ATG* Partial purification of luciferases was carried out on E. coli JM109 cells harvested in the early stationary phase then resuspended in 50mM Tris HC1 pH 8.0 containing 50mM KC1. 0.5mM dithiothreitol and 1 mM EDTA (Buffer A). Cells were broken up by disruption in a MSE soniprep (amplitude 14μ) and the lysate centrifuged at 30000 x g for 1 hour. The supernatant of the crude extract was then subjected to fractionation with ammonium sulphate and the fraction precipitated between 35% and 55% saturation contained luciferase activity and was dissolved in Buffer A and dialysed overnight against 500ml of 50mM Tris-HCl buffer pH8.0 containing 0.4mM DTT (Buffer B). Full purification of luciferases was carried out by applying the precipitated and dialysed enzyme to a Mono Q (HRlO/10) anion exchange column and eluting that with a linear gradient of 0-200mM NaCl in Buffer B (flow-rate 4ml/minute; 2ml fractions). Peak fractions containing luciferase activity were made to 50% glycerol (v/v) and stored at -20°C. Firefly luciferase (prepared from a crystalline suspension. Cat No L9009) and coenzyme A and ATP were obtained from Sigma Chemical Co. Beetle luciferin potassium salt was obtained from Promega Corporation, Madison Wisconsin, USA. Cell extracts were prepared as described in the Promega technical bulletin No 101. Aliquots of E. coli cultures were lysed in cell culture lysis reagent (25mM Tris-phosphate, pH7.8, 2mM DTT, 2mM EDTA, 10% glycerol, 1% Triton X-100, 2.5 mg/ml BSA, 1.25 mg/ml lysozyme) for 10 minutes at room temperature, centrifuged at 16000g for 2 minutes and then stored on ice prior to assay. Luciferase activity of cell lines was assayed by monitoring bioluminescence emitted by colonies b transferring these to nylon filters (Hybond N, Amersham) and then soaking the filters with 0.5m luciferin in lOOmM sodium citrate buffer pH5.0 (Wood & DeLuca, (1987) Anal Biochem 161 p501-507) at room temperature. Luciferase assays in vitro were performed at 21°C using lOOμl o assay buffer (20mM Tricine pH7.8 containing ImM MgSO 4 , O.lmM EDTA, 33.3mM DTT 0.27mM conenzyme A, 0.47mM D-luciferin, 0.53mM ATP and 1 to 5μl of sample). The final p of the assay cocktail was 7.8 and light measurements were made with a BioOrbit 1250 luminomete or in microtitre plates using a labsystems luminoskan RS plate luminometer. Protein was determined by the method of Bradford (1976) Anal. Biochem. 72 p248-254 using BS as standard. For production of non-specific chemical mutations of DNA, plasmids containing lu genes were treated according to the method of Kironde et al (1989) Biochem. J. 259, p421-42 using 0.8M hydroxylamine, ImM EDTA in O.lmM sodium phosphate pH6.0 for 2 hours at 65°C. The K m mutant was initially generated by hydroxylamine induced mutagenesis of the luc gene within pPW304 to provide plasmid 304 Gl bearing a single base change in the DNA sequence a 81 1 of SEQ ID No 1 resulting in an amino acid glutamate change to lysine at position 270. A 1.1 kb DNA fragment (BstE II/Stu I) was cloned from pPW304 and used to replace th corresponding fragment in pP601a to form pPW601Gl , thus providing a luc gene encoding fo luciferase without the four extra amino acids encoded by pPW304 (M not included from M-A-R-I Q). This mutagenised plasmid was desalted on a G60 DNA grade Nick column (Pharmacia) followe by transformation into E. coli BL21 (DE3). Luciferase expressed from this showed an identica low K m phenotype to that of the original mutant. Double stranded DNA sequencing was performed by the dideoxy chain termination method of Sanger et al (1977) Proc. Nat. Acad. Sci. (USA) 74, 5463-5467 using [alpha- 32 P]dATP and electrophoresis in 8M urea (6% wt/vol) polyacrylamide gels. Automatic sequencing was also undertaken using a DNA model 373A automated sequencer (Applied Biosystems). Assay for determining the K m value of this luciferase with respect to ATP was carried out at 21 °C with lOOμl of assay buffer (20mM tricine pH7.8 containing l.OmM MgSO 4 . O.lmM EDTA, 33mM dithiothrietol, 270μM coenzyme A, 470μM D-luciferin and 6.25 to 400μM ATP) using a luminometer to measure cpm. The K- n value for 601a-recombinant wild-type was determined to be 66.1 μM (s.e. 4.1); for 601aK (thermostable mutant 354 lysine) was 61.3 (s.e. 4.7) and for 601aGl (270 lysine K m change) was 28.7 (s.e. 0.9) thus illustrating that the 270 change more than halves the ATP concentration for which the enzyme is optimised. The effect of the 270 change on the thermostability of luciferase is negative, with X m activity being reached after only 2 minutes as compared to wild-type at 7 minutes, both at 37°C; however at 30°C the specific activity of 270 is greater than wild-type. Example 2: Preparation of 'double mutant' 270K: 354K Photinus pyralis luciferase In order to offset the reduced thermostability of the 270 change luciferase, a double chang luciferase was provided by using site directed mutagenesis to engineer the lysine change at 354 int the 270-lysine luciferases encoding DNA and plasmid described in Example 1. This involve mutation using specifically designed oligonucleotides to convert pPW601aGl to pPWόOla to G1K The oligonucleotide used to generate the 354 lysine change by SDM wa CATCCCCCTTGGGTGTAATCAG (SEQ ID No 5) with the underlined T being the mismatch. The site directed mutagenesis required to convert the glutamate 354 of pPW601aE270K. and wher required for direct synthesis of 270 mutant from pPW601 a. to desired amino acids is carried ou using the following protocol with oligonucleotides designed as required. Site Directed Mutagenesis Protocol: Plasmid selected is denatured and annealed with selection an mutagenic oligonucleotides for the desired change. The mutant DNA strand is synthesised an ligated and the whole primary restriction digested with a restriction endonuclease. Oligonucleotid primers for sequencing and SDM were synthesised using an Applied Biosystems model 380 DNA synthesiser. DNA oligonucleotide primers were designed to destroy either a unique Ava site within the luc gene or the unique Seal site within the gene for β-lactamase: the presence o these sites being used to select against plasmids that had not undergone mutagenesis. Precis protocols were as described in the Transformer Site -Directed Mutagenesis Kit (Version 2.0 sold by Clontech Laboratories lnc (US) catalog No K 1600-1 The restriction map for pPW601 derived from pDR540 and cloned luc gene is shown as Figure 4. Site directed mutagenesis was carried out as described above and in the Clontech instructions suc as to convert the wild-type Photinus luc gene inserted therein into a sequence as shown in SEQ I No 1 with expressed protein of amino acid sequence modified at position 270 as shown as Xaa i SEQ ID No 2 to Lysine. K m studies were carried out as described in Example 1 while heat inactivation studies were carrie out using crude extracts at 37°C in lysis buffer (25mM Tris phosphate pH7.8, 2mM DTT. 2m EDTA, 10% glycerol and 1% Triton X-100) at various time points aliquots of enzyme wer removed and assayed as described above (with 530μM ATP). The remaining activity was plotte against time. The K m value for 601aGlK, the double change of this example, was found to be 25.2μM (s.e. 1.5) being again less than half that of the corresponding 354 lysine mutant and the wild-type luciferase. The t| 2 value, the time after which the activity of the luciferase is reduced on continuous heating to 50% of its initial value, was found to be as follows: 601a (recombinant wild-type) t 1/2 reached after 7.0 minutes 601aGl (270 K m change) t| 2 reached after 1.75 minutes 601 aK (354 thermostable change) t ]/2 reached after >35 minutes 601aGlK (270 + 354 change) t| 2 reached after 10.5 minutes The above data is included below (plus other data) along with Km values. KmATP t|, 2 37°C (min) recombinant wild type 66.1 7.0 E270K 28.7 1.75 E354K 61.3 >35 E270K+E354K 25.2 10.5 E270R 32.0 1.75 E270Q 44.0 1.75 E270A 37.0 1.75 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: SECRETARY OF STATE FOR DEFENCE, . (ii) TITLE OF INVENTION: luciferases (iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: THE SECRETARY OF STATE FOR DEFENCE (B) STREET: WHITEHALL (C) CITY: LONDON (D) STATE: LONDON (E) COUNTRY: UNITED KINGDOM (GB) (F) ZIP: SW1A 2HB (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: WO (B) FILING DATE: (C) CLASSIFICATION: (2) INFORMATION FOR SEQ ID NO:l : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1722 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Photinus pyralis (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 4..1653 (ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(81 1..813. "") (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l : CAAATGGAAG ACGCCAAAAA CATAAAGAAA GGCCCGGCGC CATTCTATCC TCTAGAGGAT 60 GGAACCGCTG GAGAGCAACT GCATAAGGCT ATGAAGAGAT ACGCCCTGGT TCCTGGAACA 120 ATTGCTTTTA CAGATGCACA TATCGAGGTG AACATCACGT ACGCGGAATA CTTCGAAATG 180 TCCGTTCGGT TGGCAGAAGC TATGAAACGA TATGGGCTGA ATACAAATCA CAGAATCGTC 240 GTATGCAGTG AAAACTCTCT TCAATTCTTT ATGCCGGTGT TGGGCGCGTT ATTTATCGGA 300 GTTGCAGTTG CGCCCGCGAA CGACATTTAT AATGAACGTG AATTGCTCAA CAGTATGAAC 360 ATTTCGCAGC CTACCGTAGT GTTTGTTTCC AAAAAGGGGT TGCAAAAAAT TTTGAACGTG 420 CAAAAAAAAT TACCAATAAT CCAGAAAATT ATTATCATGG ATTCTAAAAC GGATTACCAG 480 GGATTTCAGT CGATGTACAC GTTCGTCACA TCTCATCTAC CTCCCGGTTT TAATGAATAC 540 GATTTTGTAC CAGAGTCCTT TGATCGTGAC AAAACAATTG CACTGATAAT GAATTCCTCT 600 GGATCTACTG GGTTACCTAA GGGTGTGGCC CTTCCGCATA GAACTGCCTG CGTCAGATTC 660 TCGCATGCCA GAGATCCTAT TTTTGGCAAT CAAATCATTC CGGATACTGC GATTTTAAGT 720 GTTGTTCCAT TCCATCACGG TTTTGGAATG TTTACTACAC TCGGATATTT GATATGTGGA 780 TTTCGAGTCG TCTTAATGTA TAGATTTGAA GAGCTGT TTTTACGATC CCTTCAGGAT 840 TACAAAATTC AAAGTGCGTT GCTAGTACCA ACCCTATTTT CATTCTTCGC CAAAAGCACT 900 CTGATTGACA AATACGATTT ATCTAATTTA CACGAAATTG CTTCTGGGGG CGCACCTCTT 960 TCGAAAGAAG TCGGGGAAGC GGTTGCAAAA CGCTTCCATC TTCCAGGGAT ACGACAAGGA 1020 TATGGGCTCA CTGAGACTAC ATCAGCTATT CT3ATTACAC CCNNNGGGGA TGATAAACCG 1080 GGCGCGGTCG GTAAAGTTGT TCCATTTTTT G J.GCGAAGG TTGTGGATCT GGATACCGGG 1140 AAAACGCTGG GCGTTAATCA GAGAGGCGAA ITATGTGTCA GAGGACCTAT GATTATGTCC 1200 GGTTATGTAA ACAATCCGGA AGCGACCAAC GCCTTGATTG ACAAGGATGG ATGGCTACAT 1260 TCTGGAGACA TAGCTTACTG GGACGAAGAC 3AACACTTCT TCATAGTTGA CCGCTTGAAG 1320 TCTTTAATTA AATACAAAGG ATATCAGGTC GCCCCCGCTG AATTGGAATC GATATTGTTA 1380 CAACACCCCA ACATCTTCGA CGCGGGCGTG GCAGGTCTTC CCGACGATGA CGCCGGTGAA 1440 CTTCCCGCCG CCGTTGTTGT TTTGGAGCA GGAAAGACGA TGACGGAAAA AGAGATCGTG 1500 GATTACGTCG CCAGTCAAGT AACAACCG G AAAAAGTTGC GCGGAGGAGT TGTGTTTGTG 1560 GACGAAGTAC CGAAAGGTCT TACCGGAAAA CTCGACGCAA GAAAAATCAG AGAGATCCTC 1620 ATAAAGGCCA AGAAGGGCGG AAAGTCCiAA TTGTAAAATG TAACTGTATT CAGCGATGAC 1680 GAAATTCTTA GCTATTGTAA TCCTCCGAGG CCTCGAGGTC GA 1722 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 550 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Photinus pyralis (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 270 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Glu Asp Ala Lys Asn l ie Lys Lys Gly Pro Ala Pro Phe Tyr Pro 1 5 10 15 Leu Glu Asp Gly Thr Ala Gly Glu Gin Leu His Lys Ala Met Lys Arg 20 25 30 Tyr Ala Leu Val Pro Gly Thr lie Ala Phe Thr Asp Ala His lie Glu 35 40 45 Val Asn lie Thr Tyr Ala Glu Tyr Phe Gl u Met Ser Val Arg Leu Ala 50 55 60 Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg lie Val Val 65 70 75 80 Cys Ser Glu Asn Ser Leu Gin Phe Phe Met Pro Val Leu Gly Ala Leu 85 90 95 Phe lie Gly Val Ala Val Ala Pro Ala Asn Asp lie Tyr Asn Glu Arg 100 105 110 Glu Leu Leu Asn Ser Met Asn lie Ser Gin Pro Thr Val Val Phe Val 115 120 125 Ser Lys Lys Gly Leu Gin Lys lie Leu Asn Val Gin Lys Lys Leu Pro 130 135 140 lie lie Gin Lys lie lie lie Met Asp Ser Lys Thr Asp Tyr Gin Gly 145 150 155 160 Phe Gin Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe 165 170 175 Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr lie 180 185 190 Ala Leu lie Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val 195 200 205 Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp 210 215 220 Pro lie Phe Gly Asn Gin lie lie Pro Asp Thr Ala lie Leu Ser Val 225 230 235 240 ?-> Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu 245 250 255 lie Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu Xaa Glu Leu 260 265 270 Phe Leu Arg Ser Leu Gin Asp Tyr Lys lie Gin Ser Ala Leu Leu Val 275 280 285 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu lie Asp Lys Tyr 290 295 300 Asp Leu Ser Asn Leu His Glu lie Ala Ser Gly Gly Ala Pro Leu Ser 305 310 315 320 Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly lie 325 330 335 Arg Gin Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala lie Leu lie Thr 340 345 350 Pro Glu Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe 355 360 365 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val 370 375 380 Asn Gin Arg Gly Glu Leu Cys Val Arg Gly Pro Met lie Met Ser Gly 385 390 395 400 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu lie Asp Lys Asp Gly 405 410 415 Trp Leu His Ser Gly Asp lie Ala Tyr Trp Asp Glu Asp Glu His Phe 420 425 430 Phe lie Val Asp Arg Leu Lys Ser Leu lie Lys Tyr Lys Gly Tyr Gin 435 440 445 Val Ala Pro Ala Glu Leu Glu Ser lie Leu Leu Gin His Pro Asn lie 450 455 460 Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu 465 470 475 480 Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys 485 490 495 Glu lie Val Asp Tyr Val Ala Ser Gin Val Thr Thr Ala Lys Lys Leu 500 505 510 Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly 515 520 525 Lys Leu Asp Ala Arg Lys lie Arg Glu lie Leu lie Lys Ala Lys Lys 530 535 540 Gly Gly Lys Ser Lys Leu 545 550 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Photinus pyralis (ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(10, "") (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GTATAGATTT GAAAAAGAGC TGTTTTTACG 30 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 550 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Photinus pyralis (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 354 (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 270 (xi)SEQUENCEDESCRIPTION: SEQIDNO:4: Met Glu Asp Ala Lys Asn lie Lys Lys Gly Pro Ala Pro Phe Tyr Pro 1 5 10 15 Leu Glu Asp Gly Thr Ala Gly Glu Gin Leu His Lys Ala Met Lys Arg 20 25 30 Tyr Ala Leu Val Pro Gly Thr lie Ala Phe Thr Asp Ala His lie Glu 35 40 45 Val Asn lie Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala 50 55 60 Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg lie Val Val 65 70 75 80 Cys Ser Glu Asn Ser Leu Gin Phe Phe Met Pro Val Leu Gly Ala Leu 85 90 95 Phe lie Gly Val Ala Val Ala Pro Ala Asn Asp lie Tyr Asn Glu Arg 100 105 110 Glu Leu Leu Asn Ser Met Asn lie Ser Gin Pro Thr Val Val Phe Val 115 120 125 Ser Lys Lys Gly Leu Gin Lys lie Leu Asn Val Gin Lys Lys Leu Pro 130 135 140 lie lie Gin Lys lie lie lie Met Asp Ser Lys Thr Asp Tyr Gin Gly 145 150 155 160 Phe Gin Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe 165 170 175 Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr lie 180 185 190 Ala Leu lie Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val 195 200 205 Ala Leu Pro His Arg Thr Leu Cys Val Arg Phe Ser His Ala Arg Asp 210 215 220 Pro lie Phe Gly Asn Gin lie lie Pro Asp Thr Ala lie Leu Ser Val 225 230 235 240 Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu 245 250 255 lie Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu Lys Glu Leu 260 265 270 Phe Leu Arg Ser Leu Gin Asp Tyr Lys lie Gin Ser Ala Leu Leu Val 275 280 285 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu lie Asp Lys Tyr 290 295 300 Asp Leu Ser Asn Leu His Glu lie Ala Ser Gly Gly Ala Pro Leu Ser 305 310 315 320 Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly lie 325 330 335 Arg Gin Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala lie Leu lie Thr 340 345 350 Pro Lys Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe 355 360 365 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val 370 375 380 Asn Gin Arg Gly Glu Leu Cys Val Arg Gly Pro Met lie Met Ser Gly 385 390 395 400 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu lie Asp Lys Asp Gly 405 41 C 415 Trp Leu His Ser Gly Asp lie Ala Tyr Trp Asp Glu Asp Glu His Phe 420 425 430 Phe lie Val Asp Arg Leu Lys Ser Leu lie Lys Tyr Lys Gly Tyr Gin 435 440 445 Val Ala Pro Ala Glu Leu Glu Ser He Leu Leu Gin His Pro Asn He 450 455 460 Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu 465 470 475 480 Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys 485 490 495 Glu He Val Asp Tyr Val Ala Ser Gin Val Thr Thr Ala Lys Lys Leu 500 505 510 Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly 515 520 525 Lys Leu Asp Ala Arg Lys He Arg Glu He Leu He Lys Ala Lys Lys 530 535 540 Gly Gly Lys Ser Lys Leu 545 550 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Photinus pyralis (ix) FEATURE: (A) NAME KEY: misc difference (B) LOCATION: replace(10, "") (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CATCCCCCTT GGGTGTAATC AG 22

Claims: CLAIMS 1. A protein having luciferase activity and having over 60% homology of amino acid sequence to luciferase from Photinus pyralis, Luciola mingrelica. Luciola cniciata or Luciola lateralis characterised in that the amino acid residue corresponding to residue 270 of Photinus pyralis luciferase or residue 272 of Luciola mingrelica. Luciola cruciata and Luciola lateralis luciferase is of an amino acid other than glutamate. 2. A protein as claimed in claim 1 characterised in that it comprises an amino acid sequence F(1)XE(2)FL wherein (1) is D or E, (2) is T or L and X is the amino acid residue other than glutamate. 3. A protein as claimed in claim 2 characterised in that it comprises an amino acid sequence TPXGDDKPGA wherein X is the amino acid residue other than glutamate. 4. A protein as claimed in claim 1, 2 or 3 characterised in that the amino acid residue X is lysine. 5. A protein as claimed in any one of claims 1 to 4 wherein the amino acid residue corresponding to that of residue 215 of Photinus pyralis luciferase or residue 217 of Luciola mingrelica. Luciola cruciata or Luciola lateralis luciferase is of a hydrophobic amino acid. 6. A protein as claimed in claim 5 wherein the residue corresponding to that of residue 215 of Photinus pyralis luciferase or residue 217 of Luciola mingrelica. Luciola cruciata or Luciola lateralis luciferase is one of isoleucine, leucine or valine or an analog of any of these. 7. A protein as claimed in any one of claims 1 to 6 wherein the amino acid residue corresponding to that of residue 354 of Photinus pyralis luciferase or residue 356 of Luciola mingrelica. Luciola cruciata or Luciola lateralis luciferase is of an amino acid other than glutamate. 8. A protein as claimed in claim 7 wherein the residue corresponding to that of residue 354 of Photinus pyralis luciferase or residue 356 of Luciola mingrelica. Luciola cruciata or Luciola lateralis luciferase is one of lysine, arginine, leucine, isoleucine or histidine or an analog of any o these. 9. A protein comprising an amino acid sequence as described in SEQ ID No 2 wherein Xaa i lysine. 10. A DNA encoding for a protein as claimed in any one of claims 1 to 9. 1 1. A DNA as claimed in claim 10 comprising a nucleotide sequence as described in SEQ I No 1 wherein the three bases N at 81 1 to 813 form a codon encoding for an amino acid other tha glutamate. 12. A DNA as claimed in claim 1 1 wherein the codon encodes for lysine. 13. A vector comprising a luc gene encoding for a protein as claimed in any one of claims 1 t 9. 14. A vector as claimed in claim 13 obtainable by treating a vector containing a wild-type o recombinant luc gene by site directed mutagenesis to change the codon responsible for encoding fo the glutamate at position 270 of Photalis pyralis luciferase or the glutamate at position 272 o Luciola mingrelica. I .nciola cruciata or Luciola lateralis luciferase to an alternative amino acid. 15. A vector as claimed in claim 14 wherein the alternative amino acid is lysine. 16. A vector as claimed in any one of claims 13 to 15 selected from pKK223-3, pDR540 an pT7-7 into which a luc gene has been ligated. 17. A cell capable of expressing a protein as claimed in any one of claims 1 to 9 comprisin DNA or a vector as claimed in any one of claims 10 to 16. 18. A cell as claimed in claim 17 being an E. coli or a S. cerevisiae. 19. A test kit for performance of an assay through measurement of ATP characterised in that the kit comprises a protein as claimed in any one of claims 1 to 9 contained within a luminescent reagent. 20. An assay method wherein ATP is measured using luciferin and luciferase to generate light the quantity of which is related to the amount of ATP characterised in that the luciferase is a protein as claimed in any one of claims 1 to 9. 21. An assay method as claimed in claim 20 wherein the assay is carried out at a temperature of 22. An assay method as claimed in claim 20 wherein the assay is carried out at a temperature of from 37°C to 60°C. 23. An assay method as claimed in claim 20 wherein the assay is carried out at a temperature of from 40°C to 50°C. 24. A protein comprising an amino acid sequence as described in SEQ ID No 2 wherein Xaa is chosen from arginine, glutamine and alanine.

Inventors: LOWE CHRISTOPHER ROBIN, MURRAY JAMES AUGUSTUS HENRY, SQUIRRELL DAVID JAMES, WHITE PETER JOHN, LOWE, CHRISTOPHER, ROBIN, MURRAY, JAMES, AUGUSTUS, HENRY, SQUIRRELL, DAVID, JAMES, WHITE, PETER, JOHN
Applicants: LOWE CHRISTOPHER ROBIN, MURRAY JAMES AUGUSTUS HENRY, SECR DEFENCE, SQUIRRELL DAVID JAMES, WHITE PETER JOHN, LOWE, CHRISTOPHER, ROBIN, MURRAY, JAMES, AUGUSTUS, HENRY, SQUIRRELL, DAVID, JAMES, THE SECRETARY OF STATE FOR DEFENCE, WHITE, PETER, JOHN
Application year: 1996
Main classification: C12N15
IPC codes: C12N1, C12N9, C12N15, C12Q1, C12R1